BACKGROUND: Whole-gland extirpation or irradiation is considered the gold standard for curative oncological treatment for localized prostate cancer, but is often associated with sexual and urinary impairment that adversely affects quality of life. This has led to increased interest in developing therapies with effective cancer control but less morbidity. We aimed to provide details of physician consensus on patient selection for prostate focal therapy (FT) in the era of contemporary prostate cancer management. METHODS: We undertook a four-stage Delphi consensus project among a panel of 47 international experts in prostate FT. Data on three main domains (role of biopsy/imaging, disease and patient factors) were collected in three iterative rounds of online questionnaires and feedback. Consensus was defined as agreement in ⩾ 80% of physicians. Finally, an in-person meeting was attended by a core group of 16 experts to review the data and formulate the consensus statement. RESULTS: Consensus was obtained in 16 of 18 subdomains. Multiparametric magnetic resonance imaging (mpMRI) is a standard imaging tool for patient selection for FT. In the presence of an mpMRI-suspicious lesion, histological confirmation is necessary prior to FT. In addition, systematic biopsy remains necessary to assess mpMRI-negative areas. However, adequate criteria for systematic biopsy remains indeterminate. FT can be recommended in D'Amico low-/intermediate-risk cancer including Gleason 4+3. Gleason 3 +4 cancer, where localized, discrete and of favorable size represents the ideal case for FT. Tumor foci o1.5 ml on mpMRI or o 20% of the prostate are suitable for FT, or up to 3 ml or 25% if localized to one hemi-gland. Gleason 3+3 at one core 1mm is acceptable in the untreated area. Preservation of sexual function is an important goal, but lack of erectile function should not exclude a patient from FT. CONCLUSIONS: This consensus provides a contemporary insight into expert opinion of patient selection for FT of clinically localized prostate cancer. 
INTRODUCTION
Whole-gland treatment of the prostate gland, either by extirpation or irradiation is considered the gold standard for curative oncological treatment of men with localized prostate cancer. 1, 2 However, after cure, many men live with sexual and urinary impairment that adversely affects their quality of life. 3 This has led to increased interest in developing therapies with effective cancer control, but less morbidity.
Localized prostate cancer has a long natural history and cancerspecific mortality is more likely in men with higher-grade disease. 4, 5 Two of the longest running active surveillance (AS) trials have also shown that men with low-grade cancer have an indolent course at 10-15 years of follow-up. 6, 7 Detailed examination of one of the cohorts with a broader inclusion criteria showed that the majority of men who developed metastasis while on observation had intermediate grade (Gleason 3+4) cancer. 8 Indeed, Gleason grade 4 harbors many more molecular hallmarks of cancer compared to Gleason grade 3. 9 Advances in imaging and targeted biopsy have improved the ability to differentiate intermediate-and high-grade cancers from indolent ones. In the past, where transrectal ultrasound-guided (TRUS) biopsy was deemed inadequate, trans-perineal template mapping biopsies were used to map cancers for targeted treatment. These require a large number of samples, tend to over-detect low-grade cancers, and can be associated with additional costs and complications. 10, 11 Multiparametric magnetic resonance imaging (mpMRI) improves staging and preferentially detects higher-grade cancers, whereas MRI-TRUS fusion systems now allow physicians to target suspicious areas accurately. [12] [13] [14] [15] The ability to better determine cancer grade and extent has led to a renewed interest in partial gland ablation treatments such as focal therapy (FT), whereby only the area of the prostate harboring clinically significant disease is treated, sparing collateral structures and resulting in less morbidity than a whole-gland approach. FT would be an ideal approach for localized smallvolume cancers of intermediate or high grade if they could be accurately targeted and treated completely, leaving areas of indolent cancer that do not pose a biological threat to be actively monitored with AS. 16 Conceptually, if detected early enough and treated effectively, this approach would alter the long-term risk of disease progression. The key to this approach is patient selection-this strategy has a greater likelihood of success when applied to an individual with a suitable disease burden.
The rate of technological and biological advances has outpaced the ability to accrue meaningful data regarding the best patient selection criteria. Many early trials were performed in men with low-risk prostate cancer who would be on AS today and early efforts in patient selection focused mainly on predicting the presence of unilateral cancer for purposes of hemiablation rather than true focal ablation. 17, 18 We aim to develop a contemporary expert consensus on patient selection for FT of prostate cancer in the era where intermediate-/ high-grade cancer could be treated focally while low-grade cancers might be monitored.
MATERIALS AND METHODS

Literature review
This consensus project was executed using the Delphi method. 19 A systematic literature search of the PubMed database was performed to review current evidence for patient selection in FT on 30 February 2016. The detailed search terms, filters and exclusions are presented in Figure 1 .
Consensus development
After reviewing the literature, experts in FT were identified and invited to participate based on clinical and research interest in prostate FT by means of reputation, authorship on this topic or peer recommendation. Three successive rounds of online survey (www.SurveyMonkey.com) were presented to the experts between 22 March and 22 June 2016. At each subsequent round, the aggregated results of the prior round were anonymously presented and the experts were allowed to modify their responses. Comments and feedback provided by experts were used to adjust existing questions or explore controversial topics in greater depth. The threshold for consensus was 80% agreement. Only experts who completed all previous rounds were included in subsequent rounds. 
RESULTS
Of 219 identified articles, 36 were deemed suitable after critical appraisal of the full text ( Figure 1 ). Issues identified were grouped into three domains for construction of the survey questionnaires: (1) role of mpMRI and biopsy, (2) disease factors and (3) patient factors.
Of 113 experts identified, 51 responded to the first round of online survey. For the second and third online rounds, the response rate was 92.1% (47 experts in each round). Participant demographics are detailed in Figure 2 . In the fourth round, 16 experts, all of whom had completed three online rounds, formed a core group to interpret the findings of the online rounds. We arrived at consensus in 16/18 subdomains of the three main domains. These are summarized in Table 1 . In addition, areas where consensus was not reached and represent controversy in patient selection for FT today are summarized in Table 2 .
Role of biopsy/imaging in patient selection for focal therapy The expert panel agreed that mpMRI is a standard imaging tool for prostate FT (92%) and is particularly important in the setting of targeted/lesional ablation (86%). The core group agreed that mpMRI should be available prior to FT whenever possible. In the presence of a suspicious mpMRI lesion (PIRADSv2 grade 4/5), histological confirmation is necessary prior to prostate FT (98%). 20 The panel agreed that MRI-TRUS software fusion biopsy is adequate (84%). No consensus was reached on the adequacy of visual estimation targeting (VET)/cognitive fusion (66% of panel in agreement) or MRI in-bore biopsy. The core group agreed that visual estimation targeting/cognitive fusion could be considered adequate in expert hands.
The panel agreed that in MRI-negative areas, systematic biopsies remain necessary even if an MRI suspicious lesion has already been sampled adequately in a targeted manner (90%). There was also strong agreement on this within the core group, with only one member feeling certain that this modus operandi would change in the near future due to improved performance of mpMRI. However, while there was consensus that o10 core TRUS Figure 1 . Details of literature review.
biopsy is insufficient (82-87% of panel in agreement), there was no agreement on an appropriate or minimum biopsy standard.
Where mpMRI is unavailable or contraindicated, the panel agreed that 12 core TRUS biopsy alone is insufficient to selected patients for FT (80%) but again, there was no agreement on what type or extent of biopsy would be sufficient.
Disease factors influencing patient selection for focal therapy In the presence of MRI-proven clinically localized disease, the panel agreed that FT is reasonable for PSA within 10 ng ml − 1 (93%) but there was neither consensus on PSA thresholds between 10 and 20 ng ml − 1 nor PSA density thresholds.
Given a situation of clinically localized disease, good life expectancy, single lesion with location/size favorable for FT, 80% of the panel agreed that FT would be the most appropriate strategy for a Gleason 3+4 lesion. The core group interpretation of this response was that a single lesion of Gleason 3+4, clinically localized in a location/size favorable for FT in a patient with good life expectancy represents the ideal case for FT.
The panel agreed that cancer foci of o 1.5 ml on mpMRI are considered suitable for FT (89-96%). The level of agreement in the panel on treating tumor foci confined to one hemi-gland up to 3 ml in size changed from 51 to 90% then 72% over rounds 1, 2 and 3, respectively. The core group agreed that cancer foci up to 3 ml on mpMRI localized to one lobe can be suitable for FT Patient selection for prostate focal therapydepending on the size of the prostate and the ability of the energy source to ablate it completely with a negative margin.
The panel agreed that a lesion comprising o 20% of the prostate volume is suitable for FT (91-93%). In rounds 2 and 3 (81% and 79%, respectively) the panel agreed that FT of a tumor occupying up to 25% of the prostate localized to one lobe was reasonable and this was adopted as consensus by the core group.
The panel agreed that FT is an acceptable strategy for tumors of up to, and including, Gleason 4+3 (80%). However, there was no clear agreement on volume thresholds: 480% of experts would treat a 3+3 lesion up to 2 ml, 67% would treat 3+3 up to 5 ml, 480% would treat 3+4 up to 2 ml, 52% would treat 3+4 up to 5 ml and 80% would treat 4+3 up to 0.5 ml. No consensus was reached on tumors of any size with a Gleason score ⩾ 4+4. • mpMRI is essential particularly in the setting of targeted/lesional ablation • mmpMRI is preferred whenever possible when FT is planned (core group) In the presence of an mpMRI-suspicious lesion (PIRADSv2 4/5), histological confirmation is necessary prior to treatment with FT MRI-TRUS fusion biopsy is adequate in assessing an mpMRI lesion prior to FT
• VET/cognitive fusion biopsy can be considered adequate in expert hands (core group) Systematic biopsies remain necessary to assess mpMRI-negative areas prior to treating a histologically confirmed mpMRI lesion Where mpMRI is unavailable or contraindicated, 12 core TRUS biopsy alone is insufficient for patient selection for FT Disease factors FT can be recommended in D'Amico low-and intermediate-risk cancer In clinically localized cancer, with good life expectancy and a single favorable lesion/size, FT is an appropriate strategy for Gleason 3+4 cancer • Gleason 3+4 cancer represents the ideal case for FT in this scenario (core group) Men with PSA ⩽ 10 ng ml − 1 are suitable for FT Cancer foci o 1.5 ml on mpMRI are suitable for FT
• Foci o3 ml but localized to one hemi-gland are suitable for FT depending on gland volume and the ability of energy source to ablate with a good margin (core group) Cancer foci occupying 20% of the prostate on mpMRI are suitable for FT
• Foci up to 25% but localized to one hemi-gland are suitable for FT (core group) FT is an acceptable strategy up to and including Gleason 4+3 Gleason 3+3 at one core, 1mm, is acceptable in the untreated area
Patient factors
Life expectancy considerations are similar to those stated in major guidelines (core group)
• There is no upper or lower boundary beyond which FT is contraindicated (core group) The potential for preservation of sexual function is an important reason for choosing FT over other whole-gland treatments
• Lack of erectile function should not exclude a patient from FT Mild to moderate LUTS is not a contraindication to FT Men with prostate volumes o 50 ml are suitable for FT
• For those with prostate volumes 450 ml, candidacy depends on location, amount of tissue requiring ablation and type of ablative energy used as long as adequate treatment of the target lesion can be achieved Abbreviations: FT, focal therapy; LUTS, lower urinary tract symptoms; mpMRI, multiparametric magnetic resonance imaging; MRI, magnetic resonance imaging; TRUS, transrectal ultrasound-guided biopsy; VET, visual estimation targeting. Statements in italics refer to core group interpretations as opposed to nonitalicized statements, which achieved a clear consensus. In the untreated zone outside of where FT was planned, the panel agreed that untreated Gleason 3+3 cancer is acceptable though there was no clear agreement on disease burden thresholds: 46% of experts would accept up to three cores of cancer, whereas 96% would accept up to one core 1 mm of cancer. The panel agreed that untreated Gleason 4+3 cancer is unacceptable at any disease burden (87%).
Patient factors influencing patient selection for focal therapy There was no consensus among the panel on a most appropriate life expectancy range for FT. The core group agreed that the minimum life expectancy for which prostate cancer treatment should be considered is defined in major guidelines and these should be adhered to when selecting patients for FT. They further agreed that there is no lower or upper limit of life expectancy beyond which FT is absolutely contraindicated, with the caveat that there is little data for FT beyond 5-year follow-up.
The panel agreed that the potential for preservation of erectile function is an important reason for choosing FT over radical treatment (93%). However, there was no agreement on a meaningful International Index for Erectile Function threshold, below which it would not be worth pursuing FT. Furthermore, the panel consensus indicates that lack of erectile function at baseline should not exclude a patient from FT: 83% of experts would not choose whole-gland ablation over FT and 72% would not choose prostatectomy/radiation over FT in a fit, young man who is impotent but has a lesion amenable to FT.
DISCUSSION
The majority of early FT trials primarily included low-risk prostate cancer patients who would today be considered suitable for AS. In the 2009 consensus meeting by de la Rosette et al., 21 the stated aim of FT was to eradicate all known prostate cancer while preserving uninvolved tissue, sparing genitourinary function. In a subsequent 2010 consensus meeting by Ahmed et al., 22 the stated aim of FT was to treat cancer and leave the benign prostate and surrounding normal structures. In another consensus meeting in 2013 by Donaldson et al., 23 the aim was to treat the dominant or index lesion. In Donaldson et al., the issue of untreated disease was first addressed and that panel agreed that it was acceptable not to treat lesions of Gleason grade 3+3 up to a length of 5mm though the issue of the type or intensity of biopsy necessary was not discussed.
In this present consensus project, we explored the theme of treating an intermediate-or high-grade lesion while leaving lowgrade cancer to be monitored with AS, thus downgrading the patient back into the AS pool. On the basis of the expert panel findings, a Gleason 3+4 lesion, when it can be completely ablated, appears to be the 'sweet spot' for FT. However, the lack of consensus regarding possible application of FT to cancers ⩾ 4+4 suggests reluctance in extending the role of FT to high-grade cancers. Regarding residual cancer to be monitored with AS, we were challenged by the broad spectrum of opinions when details were requested. While there was a strong consensus that some kind of systematic biopsy was necessary to assess the MRInegative portion of the gland before ablating a biopsy-proven mpMRI-suspicious lesion, the view on biopsy density ranged from 12 core biopsy to 1 core per ml of gland, with the only unanimity being that 8 or 10 cores are insufficient. Similarly, the wide range of opinions on acceptable untreated cancer resulted in the consensus statement adopting the lowest common denominator of opinion that only a small volume of untreated Gleason 3+3 was acceptable. Further scientific study and long-term data will be necessary to influence opinion on these topics. There is a very high level of agreement (92%) that mpMRI is a standard imaging tool to select patients for FT. The evidence for biopsy-based identification of patients with unilateral cancer is conflicting. [24] [25] [26] On the other hand, mpMRI alone or in combination with trans-perineal template mapping biopsies has been found to have a reasonable negative predictive value when selecting patients for quadrant-or hemiablation. 27, 28 Despite valuing mpMRI, our expert panel rejected the idea that FT could proceed on an mpMRI-suspicious lesion alone without prior histological confirmation. Comparatively, in the 2013 consensus meeting, 23 the experts did not come to a consensus for or against this issue.
Prior consensus panels have not addressed the issue of baseline sexual function. 29 One might argue that with poor baseline sexual function, definitive radical treatment would afford certainty in cancer control. However, while this expert panel agreed that the potential for preservation of erectile function is an important reason for choosing FT over other treatment modalities, a majority of experts would offer FT even if the patient was already impotent. Concepts that would support this notion are better preservation of continence with FT, decreased risk of adjacent organ side effects (for example, rectal toxicity) and/or the belief that one only needs to treat the cancer itself rather than the whole gland.
This consensus project should be interpreted with its limitations in mind. First, though we had a broad spectrum of experience, the experts whom we invited are active in the use and investigation of FT. Their views and experience likely do not represent those of the broader urological community. Second, the final in-person meeting comprised a core group of 16 practitioners, who may not directly represent the views of all 47 experts. With this in mind, the main role of the core group was to interpret areas where the expert panel was near consensus rather than where consensus had already been achieved. Third, our expert panel was willing to consider focal or targeted ablations, quadrant ablations as well as hemiablations as FT, consistent with a 2015 consensus on definitions in FT. 30 This heterogeneity in definitions could affect perceptions on other factors such as suitable tumor volume or percentage thresholds for FT. Fourth, the accuracy of MRI target lesion volume determination is technique dependent (lesion segmentation versus reporting of lesion diameter in three axes) and this may contribute to heterogeneity in patient selection. Last, the field of prostate FT is developing rapidly and this consensus represents the current state in the continuing evolution of patient selection. Nonetheless, until sufficient data are accrued, this consensus statement affords the best available level of evidence, based on expert opinion, for patient selection.
CONCLUSION
Prostate FT is a field with constant evolution both in technological application and understanding of biological processes. Patient selection is the cornerstone in any FT strategy. The current consensus, among experts using FT today, supports the use of FT in patients with localized intermediate-grade cancer of limited, targetable volume and AS of low-grade, low-volume outfield lesions.
